@article{e71bf8d866f446ea9453660d1c4163f6,
title = "Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype",
author = "{de Groen}, {A. L.} and {van Eijk}, Ronald and Stefan Bohringer and Wezel, {Tom van} and Richard Raghoo and Dina Ruano and Jansen, {Patty M.} and {Briaire-De Bruijn}, Inge and {de Groot}, {Fleur A.} and Karin Kleiverda and {te Boome}, Liane and Valeska Terpstra and Henriette Levenga and Alina Nicolae and Posthuma, {Eduardus F.M.} and Isabelle Focke-Snieders and Lizan Hardi and {den Hartog}, {Wietske C.E.} and Bohmer, {Lara H.} and Hogendoorn, {Pancras C.W.} and {den Berg}, {Anke van} and Arjan Diepstra and Marcel Nijland and Lugtenburg, {Pieternella J.} and Kersten, {Marie Jose} and Pals, {Steven T.} and Hendrik Veelken and Bovee, {Judith V.M.G.} and Cleven, {Arjen H.G.} and Vermaat, {Joost S.P.}",
note = "Funding Information: This study is funded by the Stichting Fonds Oncologie Holland. Funding Information: Conflict-of-interest disclosure: M.J.K. has received honoraria/ research funding from Kite Pharma, Millennium/Takeda, Mundi-pharma, Gilead Sciences, Bristol Myers Squibb, Roche, Celgene, Novartis Pharmaceuticals Corporation, and Amgen. P.J.L. has received honoraria/research funding from Takeda, Servier, Genmab, Roche, Genentech, Celgene, Incyte, and Regeneron. The remaining authors declare no competing financial interests.",
year = "2021",
month = oct,
day = "12",
doi = "10.1182/bloodadvances.2021005215",
language = "English",
volume = "5",
pages = "3760--3775",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "19",
}